Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Roth Capital Raises Price Target on Lannett (LCI) Following Acquisition of Kremers Urban Pharmaceuticals
September 3, 2015 8:18 AM EDTRoth Capital reiterated a Buy rating on Lannett Co (NYSE: LCI), and raised the price target to $68.00 (from $62.00), following the transformative acquisition of Kremers Urban Pharmaceuticals. The transaction almost doubles the revenue base for LCI, and suggests 2016 EPS accretion of mid-to-high single digits and 20-25%... More
